Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.Nicolas Girard,Byoung Chul Cho,Alexander I. Spira,Catherine A. Shu,Rachel E. Sanborn,Joel W. Neal,Melina Elpi Marmarelis,Joshua K. Sabari,Saiama Naheed Waqar,Misako Nagasaka,James Chih-Hsin Yang,Shun Lu, Pritam Kambuj, Jeffrey Sanchez, Lahila-Carina Ojeda,John Xie,Parthiv Mahadevia,Joshua Michael Bauml,Roland E. Knoblauch,Hidetoshi HayashiJOURNAL OF CLINICAL ONCOLOGY（2023）引用 0|浏览13暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
